Wegovy and Ozempic are the same drug, semaglutide, sold at different doses for different uses. Ozempic is approved for type 2 diabetes at up to 2 mg a week, while Wegovy is approved for weight management at 2.4 mg a week (up to 7.2 mg) or as a daily tablet, and in its main trial people lost an average of 14.9% of their body weight in 68 weeks.
Both curb appetite strongly, so what you eat on them matters too. This guide covers the differences first, then the nutrition. It isn't medical advice; your prescriber decides which drug and dose fit you.
Key takeaways
- Same molecule, different labels: both are once-weekly semaglutide injections from Novo Nordisk. Wegovy also comes as a 25 mg daily tablet.
- Ozempic is for type 2 diabetes; it isn't FDA-approved for weight loss. Wegovy is approved for weight management, heart risk reduction and a form of fatty liver disease.
- Higher dose, more weight loss: 14.9% on Wegovy 2.4 mg and 18.8% on 7.2 mg in trials, against about 4-6.5% on Ozempic in diabetes trials.
- Protein is the priority: about 1.2-1.6 g per kg of body weight a day, or 80-120 g, helps protect muscle.
- Strength training at least 3 times a week is part of the 2025 expert advice for anyone on these drugs.
Wegovy vs Ozempic at a glance
| Ozempic | Wegovy | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Maker | Novo Nordisk | Novo Nordisk |
| Main approved use | Type 2 diabetes | Weight management |
| Forms | Weekly injection | Weekly injection or daily tablet |
| Maintenance dose | 0.5, 1 or 2 mg weekly | 1.7 or 2.4 mg weekly (up to 7.2 mg), or 25 mg tablet daily |
| Average weight loss in trials | About 4-6.5% (people with diabetes) | 14.9% (2.4 mg, 68 weeks) |
| Approved for teens | No | Yes, 12 and older with obesity (injection) |
What each drug is approved for
According to the current FDA prescribing information (Ozempic revised May 2026, Wegovy June 2026):
Ozempic is approved for adults with type 2 diabetes to:
- improve blood sugar control, alongside diet and exercise
- lower the risk of heart attack, stroke and cardiovascular death in those with heart disease
- lower the risk of kidney function decline, kidney failure and cardiovascular death in those with chronic kidney disease
Wegovy injection is approved, with a reduced-calorie diet and more activity, to:
- reduce and keep off excess weight in adults with obesity, or overweight plus at least one weight-related condition, and in children 12 and older with obesity
- lower the risk of heart attack, stroke and cardiovascular death in adults with heart disease and obesity or overweight
- treat noncirrhotic MASH (fatty liver disease with inflammation) with moderate to advanced scarring in adults, under accelerated approval
Wegovy tablets, added to the label in December 2025, are approved for weight management and heart risk reduction in adults.
Dosing compared
Both start low and step up every 4 weeks to limit stomach side effects:
| Weeks | Ozempic weekly dose (mg) | Wegovy weekly dose (mg) |
|---|---|---|
| 1-4 | 0.25 | 0.25 |
| 5-8 | 0.5 | 0.5 |
| 9-12 | 0.5, or 1 if needed | 1 |
| 13-16 | 1, or 2 if needed | 1.7 |
| 17 onward | 0.5, 1 or 2 (max 2) | 1.7 or 2.4; up to 7.2 after at least 4 weeks on 2.4 |
Ozempic's dose is raised only if blood sugar needs it. The Wegovy tablet starts at 1.5 mg a day for 30 days and steps up monthly to 25 mg a day.
Tablet timing matters for meals. The Wegovy label says to take the tablet in the morning on an empty stomach with no more than 4 oz (120 ml) of plain water, then wait at least 30 minutes before eating, drinking anything else or taking other pills. Plan breakfast around that window.
Weight loss: what the trials show
| Trial (from the FDA labels) | Length (weeks) | Average weight change (%) |
|---|---|---|
| Wegovy 2.4 mg, adults without diabetes (STEP 1) | 68 | -14.9 (placebo -2.4) |
| Wegovy 2.4 mg, adults with type 2 diabetes | 68 | -9.6 (placebo -3.4) |
| Wegovy 7.2 mg, adults with obesity | 72 | -18.8 (2.4 mg -15.5, placebo -3.9) |
| Wegovy 25 mg tablet | 64 | -13.6 (placebo -2.4) |
| Ozempic 1 mg vs 2 mg, type 2 diabetes | 40 | about -5.7 vs -6.4 (-5.6 kg vs -6.4 kg) |
| Ozempic 0.5 mg and 1 mg, type 2 diabetes | 30 | about -4.2 and -4.9 (-3.8 kg and -4.7 kg) |
Two things explain most of the gap. Wegovy is dosed higher, and people with type 2 diabetes tend to lose less, as Wegovy's own diabetes trial shows (9.6% at the same 2.4 mg dose). In STEP 1, about 5 in 6 people on Wegovy lost at least 5% of their weight. For a month-by-month picture, see the GLP-1 weight loss timeline.
Side effects
The most common side effects on the Ozempic label are nausea, vomiting, diarrhea, stomach pain and constipation. Wegovy's list includes those plus headache, tiredness, indigestion, dizziness, bloating, burping, gas, reflux and hair loss, which reflects its higher doses and weight loss.
Both labels carry a boxed warning about thyroid C-cell tumors seen in rodents, and both say not to use them with a personal or family history of medullary thyroid cancer or MEN 2. Tell your doctor about any planned surgery, since GLP-1 drugs slow stomach emptying.
Can you use Ozempic for weight loss or switch to Wegovy?
Ozempic isn't approved for weight loss, though some doctors prescribe it off-label. Both labels say not to combine semaglutide with other semaglutide products or other GLP-1 drugs. If you're moving from one to the other, your prescriber sets the new dose and timing.
What to eat on Wegovy or Ozempic
The nutrition goals are the same on both. The difference is degree: at Wegovy's doses many people eat much less, so each meal has to do more.
Protein first
A 2025 joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society suggests:
- 1.2-1.6 g of protein per kg of body weight a day during active weight loss, or
- a simpler fixed target of 80-120 g a day, and
- not going above 2 g/kg for long periods.
For a 90 kg (198 lb) person, 1.2-1.6 g/kg is 108-144 g a day. Eat the protein part of your meal first, before you fill up. The protein calculator gives a personal target, and protein requirements on Ozempic has meal examples.
Easy options when appetite is low: Greek yogurt, cottage cheese, eggs, fish, chicken, tofu, lentils and protein shakes.
Don't let calories drop too far
The advisory flags a higher risk of nutrient shortfalls when intake falls below about 1,200 calories a day for women and 1,800 for men. Appetite on semaglutide can be low enough that some people skip meals without noticing. Logging for a few weeks shows you whether that's happening; the TDEE calculator gives a reference point for your maintenance needs.
Protect muscle
Weight lost on GLP-1 drugs isn't all fat. The advisory cites trial data in which 5.3 kg of a 13.6 kg loss (38%) was lean mass, which includes water and organs as well as muscle, and estimates that about 20% of the total was muscle. Its recommendation: strength training at least 3 times a week plus at least 150 minutes of moderate aerobic activity, alongside enough protein. Ozempic and muscle loss covers this in more detail.
Eating around nausea
Semaglutide slows how fast your stomach empties, which is why big or greasy meals often cause trouble. Common strategies:
- Eat smaller meals and stop at the first sign of fullness.
- Choose lower-fat cooking: grilled, baked or steamed over fried.
- Sip fluids through the day; the advisory stresses adequate fluids and fiber from food, especially for constipation.
- Go easy on alcohol and very sugary drinks.
For a full list, see foods that help Ozempic nausea.
Watch key nutrients
Eating less makes some nutrients harder to get. The advisory suggests considering supplements for at-risk nutrients such as vitamin D, calcium and vitamin B12, tailored to you. Ask your doctor whether blood tests make sense. GLP-1 medications and nutrient deficiencies goes through each one.
Tracking nutrition on semaglutide
With appetite this low, it's easy to hit your calorie goal while missing protein. Logging meals for even a couple of weeks shows the pattern. In Nutrify you can snap a photo of a small plate, scan a protein bar or type a quick description, and see protein next to calories for the day. Nutrify has a 7-day free trial, then a paid subscription. For a step-by-step setup, read how to track nutrition on GLP-1 with AI.
Sources
- Novo Nordisk. Wegovy (semaglutide) injection and tablets, US prescribing information, revised June 2026.
- Novo Nordisk. Ozempic (semaglutide) injection, US prescribing information, revised May 2026.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med, 2021.
- Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from ACLM, ASN, OMA and TOS. Obesity Pillars, 2025.



